Riomet Solution
FDA Recall NDC 10631-238

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 3 recorded enforcement report(s) associated with Riomet (NDC 10631-238). A significant event, classified as Class II, was initiated on Mar 31, 2021 by Sun Pharmaceutical Industries, Inc.. The reported reason for this action was: "Microbial Contamination of Non-Sterile Product"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

March 2021 Class II Recall: Microbial Contamination of Non-Sterile Product

Recall Number
Class II Terminated
Reason for Recall
Microbial Contamination of Non-Sterile Product
Initiated
Mar 31, 2021
Reported
Apr 21, 2021
Quantity
13,834 bottles

Recall Profile & Regulatory Data

Event ID
87650
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
SUN PHARMACEUTICAL INDUSTRIES INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the United States
Termination Date
Apr 14, 2022
Product Description
Riomet (metformin hydrochloride oral solution) 500 mg/5 mL Cherry Flavor, 16 fl. oz., 473 mL bottles Rx Only, Manufactured by: Mikart, LLC, Atlanta, GA 30318, Distributed by: Sun Pharmaceutical Industries Inc., Cranbury, NJ 08512, NDC 10631-206-02.
Batch or Lot Expiration Information
Lot# : J190386A, X190354A, Exp. 3/2021, J190393A, Exp. 5/2021, A200035A, Exp. 6/2021, B200064A, Exp. 8/2021; H200236A, Exp. 1/2022
Affected Packages Involved in this Recall
10631-238-01Product
10631-238-02Product
10631-206-01Product
10631-206-02Product

April 2018 Class III Recall: Labeling

Recall Number
Class III Terminated
Reason for Recall
Labeling: Not Elsewhere Classified: Sun Pharma has decided to initiate this recall in response to identified labeling discrepancies in the patient literature.
Initiated
Apr 26, 2018
Reported
May 23, 2018
Quantity
19,758 473 mL bottles

Recall Profile & Regulatory Data

Event ID
79979
Classification
Class III
Enforcement Status
Terminated
Recalling Firm
Sun Pharmaceutical Industries, Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide in the USA
Termination Date
Feb 28, 2019
Product Description
Riomet (metformin hydrochloride oral solution), 500 mg/5 mL (16 fl. oz.), 473 mL plastic bottle, Manufactured by: Mikart, Inc., Atlanta, GA 30318, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512. NDC 10631-206-02
Batch or Lot Expiration Information
Lot# Lot Numbers: E170210A, EXP 06/09/2019; F170214A, 07/05/2019; F170223A, EXP 07/06/2019; F170224A EXP 07/10/2019; F170231A , EXP 07/12/2019; F170232A EXP 07/13/2019.
Affected Packages Involved in this Recall
10631-238-01Product
10631-238-02Product
10631-206-01Product
10631-206-02Product

April 2017 Class II Recall: Microbial Contamination of Non-Sterile Products

Recall Number
Class II Terminated
Reason for Recall
Microbial Contamination of Non-Sterile Products
Initiated
Apr 18, 2017
Reported
Dec 20, 2017
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
78217
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Sun Pharmaceutical Industries, Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide
Termination Date
May 30, 2018
Product Description
Riomet (metformin hydrochloride) Oral Solution Cherry Flavored 500 mg /5 mL, 4 fl. oz. (NDC 10631-206-01) and 16 fl. oz. (NDC 10631-206-02) HDPE bottles, Rx only, Manufactured for: Ranbaxy Laboratories Inc. Jacksonville, FL 32257 USA, Distributed by: Sun Pharmaceutical Industries, Cranbury, NJ 08512
Batch or Lot Expiration Information
Lot# A
Lot# 160031A, A160031B; Exp. 11/17
Affected Packages Involved in this Recall
10631-238-01Product
10631-238-02Product
10631-206-01Product
10631-206-02Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.